Home › Blood Cancers › District of Columbia
Blood Cancers clinical trials in District of Columbia
7 studies for Blood Cancers are looking for participants at sites in District of Columbia.
Cities in District of Columbia
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- MedStar Georgetown University Hospital, Washington D.C.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT03816345Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
- Childrens National Medical Center, Washington D.C.
RecruitingPhase 1
6 Months – 80 Years · All sexes · Updated Aug 14, 2026 · NCT02203903Mosaic Trial for Stem Cell Transplant Recipients
- Georgetown University School of Medicine, Washington D.C.
Recruiting
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT06960993A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Children's National Medical Center, Washington D.C.
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
- George Washington University, Washington D.C.
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT05663502Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's National Medical Center, Washington D.C.
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.